Skip to main content

Site notifications

Australian Public Assessment Reports (AusPAR)

Search our AusPAR dataset.

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

1074 result(s) found, displaying 276 to 300
  • Forxiga (dapagliflozin) has been approved for the treatment of symptomatic heart failure with reduced ejection fraction, as an adjunct to standard of care therapy, in adults.
  • Australian Public Assessment Report for Guselkumab
  • Australian Public Assessment Report for Ciclosporin
  • Australian Public Assessment Report for Labetalol hydrochloride
  • Australian Public Assessment Report for Tucatinib
  • Australian Public Assessment Report for Trifarotene
  • Australian Public Assessment Report for Afamelanotide
  • Australian Public Assessment Report for Brexpiprazole
  • Australian Public Assessment Report for Insulin aspart
  • Australian Public Assessment Report for Nintedanib (as Esilate)
  • Australian Public Assessment Report for Etanercept
  • Australian Public Assessment Report for Opicapone
  • Australian Public Assessment Report for Secukinumab
  • Australian Public Assessment Report for Teriparatide
  • Australian Public Assessment Report for Cannabidiol
  • Australian Public Assessment Report for Iodised oil
  • Australian Public Assessment Report for Flucelvax Quad (quadrivalent influenza vaccine) for the prevention of of influenza in adults and children 9 years and older
  • Australian Public Assessment Report for Larotrectinib
  • Australian Public Assessment Report for Entrectinib
  • Australian Public Assessment Report for Voretigene neparvovec

Help us improve this page